APO Research
Talk to an analyst

APO RESEARCH · REPORT

Antidiabetic Thiazolidinediones

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Antidiabetic Thiazolidinediones Market Outlook and Growth Opportunities 2026

20 December 2025191 pages

Choose your research edition.

Industry ResearchAntidiabetic Thiazolidinediones Industry Research Report 2026126 pages · $2,950 USDIndustry Growth & TrendsGlobal Antidiabetic Thiazolidinediones Industry Growth and Trends Forecast to 2032100 pages · $3,450 USDMarket StructureGlobal Antidiabetic Thiazolidinediones Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032197 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Antidiabetic Thiazolidinediones Market Outlook and Growth Opportunities 2026191 pages · $4,250 USDMarket Analysis & ForecastGlobal Antidiabetic Thiazolidinediones Market Analysis and Forecast 2026-2032191 pages · $4,950 USD

Market perspective

The global Antidiabetic Thiazolidinediones market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Antidiabetic Thiazolidinediones is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Antidiabetic Thiazolidinediones is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Antidiabetic Thiazolidinediones is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Antidiabetic Thiazolidinediones market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Antidiabetic Thiazolidinediones market include Takeda Pharmaceuticals, Sanofi, Merck & Co., Eli Lilly, Pfizer, GlaxoSmithKline, AstraZeneca, Novo Nordisk and Bristol-Myers Squibb, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Antidiabetic Thiazolidinediones market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Antidiabetic Thiazolidinediones and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Antidiabetic Thiazolidinediones sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Antidiabetic Thiazolidinediones market size, projected growth trends, production technologies, key applications, and end-use industries.

Antidiabetic Thiazolidinediones Segment by Company

Takeda Pharmaceuticals

Sanofi

Merck & Co.

Eli Lilly

Pfizer

GlaxoSmithKline

AstraZeneca

Novo Nordisk

Bristol-Myers Squibb

Boehringer Ingelheim

Antidiabetic Thiazolidinediones Segment by Type

Rosiglitazone

Pioglitazone

Antidiabetic Thiazolidinediones Segment by Application

Hospitals

Clinics

Other

Antidiabetic Thiazolidinediones Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Antidiabetic Thiazolidinediones status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Antidiabetic Thiazolidinediones market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Antidiabetic Thiazolidinediones significant trends, drivers, influence factors in global and regions.

6. To analyze Antidiabetic Thiazolidinediones competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Antidiabetic Thiazolidinediones market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Antidiabetic Thiazolidinediones and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Antidiabetic Thiazolidinediones.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Antidiabetic Thiazolidinediones market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Antidiabetic Thiazolidinediones industry.

Chapter 3: Detailed analysis of Antidiabetic Thiazolidinediones manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Antidiabetic Thiazolidinediones in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Antidiabetic Thiazolidinediones in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Antidiabetic Thiazolidinediones Industry Trends Table 2. Antidiabetic Thiazolidinediones Industry Drivers Table 3. Antidiabetic Thiazolidinediones Industry Opportunities and Challenges Table 4. Antidiabetic Thiazolidinediones Industry Restraints Table 5. Global Antidiabetic Thiazolidinediones Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Antidiabetic Thiazolidinediones Revenue Share by Company (2021-2026) Table 7. Global Antidiabetic Thiazolidinediones Sales Volume by Company (K Units) & (2021-2026) Table 8. Global Antidiabetic Thiazolidinediones Sales Volume Share by Company (2021-2026) Table 9. Global Antidiabetic Thiazolidinediones Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Antidiabetic Thiazolidinediones Company Ranking, (2024-2026) & (USD Million) Table 11. Global Antidiabetic Thiazolidinediones Key Company Manufacturing Base & Headquarters Table 12. Global Antidiabetic Thiazolidinediones Company, Product Type & Application Table 13. Global Antidiabetic Thiazolidinediones Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Antidiabetic Thiazolidinediones by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Rosiglitazone Table 18. Significant Companies of Pioglitazone Table 19. Global Antidiabetic Thiazolidinediones Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 20. Global Antidiabetic Thiazolidinediones Sales Volume by Type (2021-2026) & (K Units) Table 21. Global Antidiabetic Thiazolidinediones Sales Volume by Type (2027-2032) & (K Units) Table 22. Global Antidiabetic Thiazolidinediones Sales Volume Share by Type (2021-2026) Table 23. Global Antidiabetic Thiazolidinediones Sales Volume Share by Type (2027-2032) Table 24. Global Antidiabetic Thiazolidinediones Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Antidiabetic Thiazolidinediones Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global Antidiabetic Thiazolidinediones Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global Antidiabetic Thiazolidinediones Sales Value Share by Type (2021-2026) Table 28. Global Antidiabetic Thiazolidinediones Sales Value Share by Type (2027-2032) Table 29. Significant Companies of Hospitals Table 30. Significant Companies of Clinics Table 31. Significant Companies of Other Table 32. Global Antidiabetic Thiazolidinediones Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 33. Global Antidiabetic Thiazolidinediones Sales Volume by Application (2021-2026) & (K Units) Table 34. Global Antidiabetic Thiazolidinediones Sales Volume by Application (2027-2032) & (K Units) Table 35. Global Antidiabetic Thiazolidinediones Sales Volume Share by Application (2021-2026) Table 36. Global Antidiabetic Thiazolidinediones Sales Volume Share by Application (2027-2032) Table 37. Global Antidiabetic Thiazolidinediones Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 38. Global Antidiabetic Thiazolidinediones Sales Value by Application (2021-2026) & (US$ Million) Table 39. Global Antidiabetic Thiazolidinediones Sales Value by Application (2027-2032) & (US$ Million) Table 40. Global Antidiabetic Thiazolidinediones Sales Value Share by Application (2021-2026) Table 41. Global Antidiabetic Thiazolidinediones Sales Value Share by Application (2027-2032) Table 42. Global Antidiabetic Thiazolidinediones Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 43. Global Antidiabetic Thiazolidinediones Sales by Region (2021-2026) & (K Units) Table 44. Global Antidiabetic Thiazolidinediones Sales Market Share by Region (2021-2026) Table 45. Global Antidiabetic Thiazolidinediones Sales by Region (2027-2032) & (K Units) Table 46. Global Antidiabetic Thiazolidinediones Sales Market Share by Region (2027-2032) Table 47. Global Antidiabetic Thiazolidinediones Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 48. Global Antidiabetic Thiazolidinediones Sales Value by Region (2021-2026) & (US$ Million) Table 49. Global Antidiabetic Thiazolidinediones Sales Value Share by Region (2021-2026) Table 50. Global Antidiabetic Thiazolidinediones Sales Value by Region (2027-2032) & (US$ Million) Table 51. Global Antidiabetic Thiazolidinediones Sales Value Share by Region (2027-2032) Table 52. Global Antidiabetic Thiazolidinediones Market Average Price (US$/Unit) by Region (2021-2026) Table 53. Global Antidiabetic Thiazolidinediones Market Average Price (US$/Unit) by Region (2027-2032) Table 54. Global Antidiabetic Thiazolidinediones Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 55. Global Antidiabetic Thiazolidinediones Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 56. Global Antidiabetic Thiazolidinediones Sales by Country (2021-2026) & (K Units) Table 57. Global Antidiabetic Thiazolidinediones Sales Market Share by Country (2021-2026) Table 58. Global Antidiabetic Thiazolidinediones Sales by Country (2027-2032) & (K Units) Table 59. Global Antidiabetic Thiazolidinediones Sales Market Share by Country (2027-2032) Table 60. Global Antidiabetic Thiazolidinediones Sales Value by Country (2021-2026) & (US$ Million) Table 61. Global Antidiabetic Thiazolidinediones Sales Value Market Share by Country (2021-2026) Table 62. Global Antidiabetic Thiazolidinediones Sales Value by Country (2027-2032) & (US$ Million) Table 63. Global Antidiabetic Thiazolidinediones Sales Value Market Share by Country (2027-2032) Table 64. Takeda Pharmaceuticals Company Information Table 65. Takeda Pharmaceuticals Business Overview Table 66. Takeda Pharmaceuticals Antidiabetic Thiazolidinediones Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 67. Takeda Pharmaceuticals Antidiabetic Thiazolidinediones Product Portfolio Table 68. Takeda Pharmaceuticals Recent Development Table 69. Sanofi Company Information Table 70. Sanofi Business Overview Table 71. Sanofi Antidiabetic Thiazolidinediones Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 72. Sanofi Antidiabetic Thiazolidinediones Product Portfolio Table 73. Sanofi Recent Development Table 74. Merck & Co. Company Information Table 75. Merck & Co. Business Overview Table 76. Merck & Co. Antidiabetic Thiazolidinediones Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 77. Merck & Co. Antidiabetic Thiazolidinediones Product Portfolio Table 78. Merck & Co. Recent Development Table 79. Eli Lilly Company Information Table 80. Eli Lilly Business Overview Table 81. Eli Lilly Antidiabetic Thiazolidinediones Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 82. Eli Lilly Antidiabetic Thiazolidinediones Product Portfolio Table 83. Eli Lilly Recent Development Table 84. Pfizer Company Information Table 85. Pfizer Business Overview Table 86. Pfizer Antidiabetic Thiazolidinediones Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 87. Pfizer Antidiabetic Thiazolidinediones Product Portfolio Table 88. Pfizer Recent Development Table 89. GlaxoSmithKline Company Information Table 90. GlaxoSmithKline Business Overview Table 91. GlaxoSmithKline Antidiabetic Thiazolidinediones Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 92. GlaxoSmithKline Antidiabetic Thiazolidinediones Product Portfolio Table 93. GlaxoSmithKline Recent Development Table 94. AstraZeneca Company Information Table 95. AstraZeneca Business Overview Table 96. AstraZeneca Antidiabetic Thiazolidinediones Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 97. AstraZeneca Antidiabetic Thiazolidinediones Product Portfolio Table 98. AstraZeneca Recent Development Table 99. Novo Nordisk Company Information Table 100. Novo Nordisk Business Overview Table 101. Novo Nordisk Antidiabetic Thiazolidinediones Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 102. Novo Nordisk Antidiabetic Thiazolidinediones Product Portfolio Table 103. Novo Nordisk Recent Development Table 104. Bristol-Myers Squibb Company Information Table 105. Bristol-Myers Squibb Business Overview Table 106. Bristol-Myers Squibb Antidiabetic Thiazolidinediones Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 107. Bristol-Myers Squibb Antidiabetic Thiazolidinediones Product Portfolio Table 108. Bristol-Myers Squibb Recent Development Table 109. Boehringer Ingelheim Company Information Table 110. Boehringer Ingelheim Business Overview Table 111. Boehringer Ingelheim Antidiabetic Thiazolidinediones Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 112. Boehringer Ingelheim Antidiabetic Thiazolidinediones Product Portfolio Table 113. Boehringer Ingelheim Recent Development Table 114. Key Raw Materials Table 115. Raw Materials Key Suppliers Table 116. Antidiabetic Thiazolidinediones Distributors List Table 117. Antidiabetic Thiazolidinediones Customers List Table 118. Research Programs/Design for This Report Table 119. Authors List of This Report Table 120. Secondary Sources Table 121. Primary Sources List of Figures Figure 1. Antidiabetic Thiazolidinediones Product Image Figure 2. Global Antidiabetic Thiazolidinediones Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Antidiabetic Thiazolidinediones Sales Value (2021-2032) & (US$ Million) Figure 4. Global Antidiabetic Thiazolidinediones Sales (2021-2032) & (K Units) Figure 5. Global Antidiabetic Thiazolidinediones Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Antidiabetic Thiazolidinediones Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Rosiglitazone Image Figure 10. Pioglitazone Image Figure 11. Global Antidiabetic Thiazolidinediones Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 12. Global Antidiabetic Thiazolidinediones Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global Antidiabetic Thiazolidinediones Sales Volume Share by Type (2021-2032) Figure 14. Global Antidiabetic Thiazolidinediones Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Antidiabetic Thiazolidinediones Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Antidiabetic Thiazolidinediones Sales Value Share by Type (2021-2032) Figure 17. Hospitals Image Figure 18. Clinics Image Figure 19. Other Image Figure 20. Global Antidiabetic Thiazolidinediones Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 21. Global Antidiabetic Thiazolidinediones Sales Volume Share 2021 VS 2025 VS 2032 Figure 22. Global Antidiabetic Thiazolidinediones Sales Volume Share by Application (2021-2032) Figure 23. Global Antidiabetic Thiazolidinediones Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 24. Global Antidiabetic Thiazolidinediones Sales Value Share 2021 VS 2025 VS 2032 Figure 25. Global Antidiabetic Thiazolidinediones Sales Value Share by Application (2021-2032) Figure 26. Global Antidiabetic Thiazolidinediones Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 27. Global Antidiabetic Thiazolidinediones Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 28. Global Antidiabetic Thiazolidinediones Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 29. Global Antidiabetic Thiazolidinediones Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 30. North America Antidiabetic Thiazolidinediones Sales Value (2021-2032) & (US$ Million) Figure 31. North America Antidiabetic Thiazolidinediones Sales Value Share by Country (%), 2025 VS 2032 Figure 32. Europe Antidiabetic Thiazolidinediones Sales Value (2021-2032) & (US$ Million) Figure 33. Europe Antidiabetic Thiazolidinediones Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Asia-Pacific Antidiabetic Thiazolidinediones Sales Value (2021-2032) & (US$ Million) Figure 35. Asia-Pacific Antidiabetic Thiazolidinediones Sales Value Share by Country (%), 2025 VS 2032 Figure 36. South America Antidiabetic Thiazolidinediones Sales Value (2021-2032) & (US$ Million) Figure 37. South America Antidiabetic Thiazolidinediones Sales Value Share by Country (%), 2025 VS 2032 Figure 38. Middle East & Africa Antidiabetic Thiazolidinediones Sales Value (2021-2032) & (US$ Million) Figure 39. Middle East & Africa Antidiabetic Thiazolidinediones Sales Value Share by Country (%), 2025 VS 2032 Figure 40. USA Antidiabetic Thiazolidinediones Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. USA Antidiabetic Thiazolidinediones Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. USA Antidiabetic Thiazolidinediones Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. Canada Antidiabetic Thiazolidinediones Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. Canada Antidiabetic Thiazolidinediones Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. Canada Antidiabetic Thiazolidinediones Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. Mexico Antidiabetic Thiazolidinediones Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. Mexico Antidiabetic Thiazolidinediones Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. Mexico Antidiabetic Thiazolidinediones Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Germany Antidiabetic Thiazolidinediones Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Germany Antidiabetic Thiazolidinediones Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Germany Antidiabetic Thiazolidinediones Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. France Antidiabetic Thiazolidinediones Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. France Antidiabetic Thiazolidinediones Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. France Antidiabetic Thiazolidinediones Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. U.K. Antidiabetic Thiazolidinediones Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. U.K. Antidiabetic Thiazolidinediones Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. U.K. Antidiabetic Thiazolidinediones Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Italy Antidiabetic Thiazolidinediones Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Italy Antidiabetic Thiazolidinediones Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Italy Antidiabetic Thiazolidinediones Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Spain Antidiabetic Thiazolidinediones Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Spain Antidiabetic Thiazolidinediones Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Spain Antidiabetic Thiazolidinediones Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Russia Antidiabetic Thiazolidinediones Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Russia Antidiabetic Thiazolidinediones Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Russia Antidiabetic Thiazolidinediones Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Netherlands Antidiabetic Thiazolidinediones Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Netherlands Antidiabetic Thiazolidinediones Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Netherlands Antidiabetic Thiazolidinediones Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Nordic Countries Antidiabetic Thiazolidinediones Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Nordic Countries Antidiabetic Thiazolidinediones Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Nordic Countries Antidiabetic Thiazolidinediones Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. China Antidiabetic Thiazolidinediones Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. China Antidiabetic Thiazolidinediones Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. China Antidiabetic Thiazolidinediones Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Japan Antidiabetic Thiazolidinediones Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Japan Antidiabetic Thiazolidinediones Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Japan Antidiabetic Thiazolidinediones Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. South Korea Antidiabetic Thiazolidinediones Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. South Korea Antidiabetic Thiazolidinediones Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. South Korea Antidiabetic Thiazolidinediones Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. India Antidiabetic Thiazolidinediones Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. India Antidiabetic Thiazolidinediones Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. India Antidiabetic Thiazolidinediones Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Australia Antidiabetic Thiazolidinediones Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Australia Antidiabetic Thiazolidinediones Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Australia Antidiabetic Thiazolidinediones Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Southeast Asia Antidiabetic Thiazolidinediones Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Southeast Asia Antidiabetic Thiazolidinediones Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Southeast Asia Antidiabetic Thiazolidinediones Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Brazil Antidiabetic Thiazolidinediones Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Brazil Antidiabetic Thiazolidinediones Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Brazil Antidiabetic Thiazolidinediones Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Argentina Antidiabetic Thiazolidinediones Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Argentina Antidiabetic Thiazolidinediones Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Argentina Antidiabetic Thiazolidinediones Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Chile Antidiabetic Thiazolidinediones Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Chile Antidiabetic Thiazolidinediones Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Chile Antidiabetic Thiazolidinediones Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Colombia Antidiabetic Thiazolidinediones Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Colombia Antidiabetic Thiazolidinediones Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Colombia Antidiabetic Thiazolidinediones Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Peru Antidiabetic Thiazolidinediones Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Peru Antidiabetic Thiazolidinediones Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Peru Antidiabetic Thiazolidinediones Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Saudi Arabia Antidiabetic Thiazolidinediones Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Saudi Arabia Antidiabetic Thiazolidinediones Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Saudi Arabia Antidiabetic Thiazolidinediones Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Israel Antidiabetic Thiazolidinediones Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Israel Arabia Antidiabetic Thiazolidinediones Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Israel Arabia Antidiabetic Thiazolidinediones Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. UAE Antidiabetic Thiazolidinediones Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. UAE Antidiabetic Thiazolidinediones Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. UAE Antidiabetic Thiazolidinediones Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Turkey Antidiabetic Thiazolidinediones Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. Turkey Antidiabetic Thiazolidinediones Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. Turkey Antidiabetic Thiazolidinediones Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Iran Antidiabetic Thiazolidinediones Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. Iran Antidiabetic Thiazolidinediones Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. Iran Antidiabetic Thiazolidinediones Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. Egypt Antidiabetic Thiazolidinediones Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 122. Egypt Antidiabetic Thiazolidinediones Sales Value Share by Type, 2025 VS 2032 & (%) Figure 123. Egypt Antidiabetic Thiazolidinediones Sales Value Share by Application, 2025 VS 2032 & (%) Figure 124. Antidiabetic Thiazolidinediones Value Chain Figure 125. Manufacturing Cost Structure Figure 126. Antidiabetic Thiazolidinediones Sales Mode & Process Figure 127. Direct Comparison with Distribution Share Figure 128. Distributors Profiles Figure 129. Years Considered Figure 130. Research Process Figure 131. Key Executives Interviewed

Scope & coverage.

Types
  • Rosiglitazone
  • Pioglitazone
Applications
  • Hospitals
  • Clinics
  • Other
Companies covered
  • Takeda Pharmaceuticals
  • Sanofi
  • Merck & Co.
  • Eli Lilly
  • Pfizer
  • GlaxoSmithKline
  • AstraZeneca
  • Novo Nordisk
  • Bristol-Myers Squibb
  • Boehringer Ingelheim

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Antidiabetic Thiazolidinediones Sales Value (2021-2032)
  4. 1.2.2 Global Antidiabetic Thiazolidinediones Sales Volume (2021-2032)
  5. 1.2.3 Global Antidiabetic Thiazolidinediones Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Antidiabetic Thiazolidinediones Market Dynamics
  1. 2.1 Antidiabetic Thiazolidinediones Industry Trends
  2. 2.2 Antidiabetic Thiazolidinediones Industry Drivers
  3. 2.3 Antidiabetic Thiazolidinediones Industry Opportunities and Challenges
  4. 2.4 Antidiabetic Thiazolidinediones Industry Restraints
3 Antidiabetic Thiazolidinediones Market by Company
  1. 3.1 Global Antidiabetic Thiazolidinediones Company Revenue Ranking in 2025
  2. 3.2 Global Antidiabetic Thiazolidinediones Revenue by Company (2021-2026)
  3. 3.3 Global Antidiabetic Thiazolidinediones Sales Volume by Company (2021-2026)
  4. 3.4 Global Antidiabetic Thiazolidinediones Average Price by Company (2021-2026)
  5. 3.5 Global Antidiabetic Thiazolidinediones Company Ranking (2024-2026)
  6. 3.6 Global Antidiabetic Thiazolidinediones Company Manufacturing Base and Headquarters
  7. 3.7 Global Antidiabetic Thiazolidinediones Company Product Type and Application
  8. 3.8 Global Antidiabetic Thiazolidinediones Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Antidiabetic Thiazolidinediones Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Antidiabetic Thiazolidinediones Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Antidiabetic Thiazolidinediones Market by Type
  1. 4.1 Antidiabetic Thiazolidinediones Type Introduction
  2. 4.1.1 Rosiglitazone
  3. 4.1.2 Pioglitazone
  4. 4.2 Global Antidiabetic Thiazolidinediones Sales Volume by Type
  5. 4.2.1 Global Antidiabetic Thiazolidinediones Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Antidiabetic Thiazolidinediones Sales Volume by Type (2021-2032)
  7. 4.2.3 Global Antidiabetic Thiazolidinediones Sales Volume Share by Type (2021-2032)
  8. 4.3 Global Antidiabetic Thiazolidinediones Sales Value by Type
  9. 4.3.1 Global Antidiabetic Thiazolidinediones Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Antidiabetic Thiazolidinediones Sales Value by Type (2021-2032)
  11. 4.3.3 Global Antidiabetic Thiazolidinediones Sales Value Share by Type (2021-2032)
5 Antidiabetic Thiazolidinediones Market by Application
  1. 5.1 Antidiabetic Thiazolidinediones Application Introduction
  2. 5.1.1 Hospitals
  3. 5.1.2 Clinics
  4. 5.1.3 Other
  5. 5.2 Global Antidiabetic Thiazolidinediones Sales Volume by Application
  6. 5.2.1 Global Antidiabetic Thiazolidinediones Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Antidiabetic Thiazolidinediones Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Antidiabetic Thiazolidinediones Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Antidiabetic Thiazolidinediones Sales Value by Application
  10. 5.3.1 Global Antidiabetic Thiazolidinediones Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Antidiabetic Thiazolidinediones Sales Value by Application (2021-2032)
  12. 5.3.3 Global Antidiabetic Thiazolidinediones Sales Value Share by Application (2021-2032)
6 Antidiabetic Thiazolidinediones Regional Sales and Value Analysis
  1. 6.1 Global Antidiabetic Thiazolidinediones Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Antidiabetic Thiazolidinediones Sales by Region (2021-2032)
  3. 6.2.1 Global Antidiabetic Thiazolidinediones Sales by Region: 2021-2026
  4. 6.2.2 Global Antidiabetic Thiazolidinediones Sales by Region (2027-2032)
  5. 6.3 Global Antidiabetic Thiazolidinediones Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Antidiabetic Thiazolidinediones Sales Value by Region (2021-2032)
  7. 6.4.1 Global Antidiabetic Thiazolidinediones Sales Value by Region: 2021-2026
  8. 6.4.2 Global Antidiabetic Thiazolidinediones Sales Value by Region (2027-2032)
  9. 6.5 Global Antidiabetic Thiazolidinediones Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Antidiabetic Thiazolidinediones Sales Value (2021-2032)
  12. 6.6.2 North America Antidiabetic Thiazolidinediones Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Antidiabetic Thiazolidinediones Sales Value (2021-2032)
  15. 6.7.2 Europe Antidiabetic Thiazolidinediones Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Antidiabetic Thiazolidinediones Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Antidiabetic Thiazolidinediones Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Antidiabetic Thiazolidinediones Sales Value (2021-2032)
  21. 6.9.2 South America Antidiabetic Thiazolidinediones Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Antidiabetic Thiazolidinediones Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Antidiabetic Thiazolidinediones Sales Value Share by Country, 2025 VS 2032
7 Antidiabetic Thiazolidinediones Country-level Sales and Value Analysis
  1. 7.1 Global Antidiabetic Thiazolidinediones Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Antidiabetic Thiazolidinediones Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Antidiabetic Thiazolidinediones Sales by Country (2021-2032)
  4. 7.3.1 Global Antidiabetic Thiazolidinediones Sales by Country (2021-2026)
  5. 7.3.2 Global Antidiabetic Thiazolidinediones Sales by Country (2027-2032)
  6. 7.4 Global Antidiabetic Thiazolidinediones Sales Value by Country (2021-2032)
  7. 7.4.1 Global Antidiabetic Thiazolidinediones Sales Value by Country (2021-2026)
  8. 7.4.2 Global Antidiabetic Thiazolidinediones Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Antidiabetic Thiazolidinediones Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Antidiabetic Thiazolidinediones Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Antidiabetic Thiazolidinediones Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Antidiabetic Thiazolidinediones Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Antidiabetic Thiazolidinediones Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Antidiabetic Thiazolidinediones Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Antidiabetic Thiazolidinediones Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Antidiabetic Thiazolidinediones Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Antidiabetic Thiazolidinediones Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Antidiabetic Thiazolidinediones Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Antidiabetic Thiazolidinediones Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Antidiabetic Thiazolidinediones Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Antidiabetic Thiazolidinediones Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Antidiabetic Thiazolidinediones Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Antidiabetic Thiazolidinediones Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Antidiabetic Thiazolidinediones Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Antidiabetic Thiazolidinediones Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Antidiabetic Thiazolidinediones Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Antidiabetic Thiazolidinediones Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Antidiabetic Thiazolidinediones Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Antidiabetic Thiazolidinediones Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Antidiabetic Thiazolidinediones Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Antidiabetic Thiazolidinediones Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Antidiabetic Thiazolidinediones Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Antidiabetic Thiazolidinediones Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Antidiabetic Thiazolidinediones Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Antidiabetic Thiazolidinediones Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Antidiabetic Thiazolidinediones Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Antidiabetic Thiazolidinediones Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Antidiabetic Thiazolidinediones Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Antidiabetic Thiazolidinediones Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Antidiabetic Thiazolidinediones Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Antidiabetic Thiazolidinediones Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Antidiabetic Thiazolidinediones Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Antidiabetic Thiazolidinediones Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Antidiabetic Thiazolidinediones Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Antidiabetic Thiazolidinediones Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Antidiabetic Thiazolidinediones Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Antidiabetic Thiazolidinediones Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Antidiabetic Thiazolidinediones Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Antidiabetic Thiazolidinediones Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Antidiabetic Thiazolidinediones Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Antidiabetic Thiazolidinediones Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Antidiabetic Thiazolidinediones Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Antidiabetic Thiazolidinediones Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Antidiabetic Thiazolidinediones Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Antidiabetic Thiazolidinediones Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Antidiabetic Thiazolidinediones Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Antidiabetic Thiazolidinediones Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Antidiabetic Thiazolidinediones Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Antidiabetic Thiazolidinediones Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Antidiabetic Thiazolidinediones Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Antidiabetic Thiazolidinediones Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Antidiabetic Thiazolidinediones Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Antidiabetic Thiazolidinediones Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Antidiabetic Thiazolidinediones Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Antidiabetic Thiazolidinediones Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Antidiabetic Thiazolidinediones Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Antidiabetic Thiazolidinediones Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Antidiabetic Thiazolidinediones Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Antidiabetic Thiazolidinediones Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Antidiabetic Thiazolidinediones Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Antidiabetic Thiazolidinediones Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Antidiabetic Thiazolidinediones Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Antidiabetic Thiazolidinediones Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Antidiabetic Thiazolidinediones Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Antidiabetic Thiazolidinediones Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Antidiabetic Thiazolidinediones Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Antidiabetic Thiazolidinediones Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Antidiabetic Thiazolidinediones Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Antidiabetic Thiazolidinediones Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Antidiabetic Thiazolidinediones Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Antidiabetic Thiazolidinediones Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Antidiabetic Thiazolidinediones Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Antidiabetic Thiazolidinediones Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Antidiabetic Thiazolidinediones Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Antidiabetic Thiazolidinediones Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Antidiabetic Thiazolidinediones Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Antidiabetic Thiazolidinediones Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Antidiabetic Thiazolidinediones Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Antidiabetic Thiazolidinediones Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Antidiabetic Thiazolidinediones Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Antidiabetic Thiazolidinediones Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Antidiabetic Thiazolidinediones Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Takeda Pharmaceuticals
  2. 8.1.1 Takeda Pharmaceuticals Company Information
  3. 8.1.2 Takeda Pharmaceuticals Business Overview
  4. 8.1.3 Takeda Pharmaceuticals Antidiabetic Thiazolidinediones Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Takeda Pharmaceuticals Antidiabetic Thiazolidinediones Product Portfolio
  6. 8.1.5 Takeda Pharmaceuticals Recent Developments
  7. 8.2 Sanofi
  8. 8.2.1 Sanofi Company Information
  9. 8.2.2 Sanofi Business Overview
  10. 8.2.3 Sanofi Antidiabetic Thiazolidinediones Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Sanofi Antidiabetic Thiazolidinediones Product Portfolio
  12. 8.2.5 Sanofi Recent Developments
  13. 8.3 Merck & Co.
  14. 8.3.1 Merck & Co. Company Information
  15. 8.3.2 Merck & Co. Business Overview
  16. 8.3.3 Merck & Co. Antidiabetic Thiazolidinediones Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Merck & Co. Antidiabetic Thiazolidinediones Product Portfolio
  18. 8.3.5 Merck & Co. Recent Developments
  19. 8.4 Eli Lilly
  20. 8.4.1 Eli Lilly Company Information
  21. 8.4.2 Eli Lilly Business Overview
  22. 8.4.3 Eli Lilly Antidiabetic Thiazolidinediones Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Eli Lilly Antidiabetic Thiazolidinediones Product Portfolio
  24. 8.4.5 Eli Lilly Recent Developments
  25. 8.5 Pfizer
  26. 8.5.1 Pfizer Company Information
  27. 8.5.2 Pfizer Business Overview
  28. 8.5.3 Pfizer Antidiabetic Thiazolidinediones Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Pfizer Antidiabetic Thiazolidinediones Product Portfolio
  30. 8.5.5 Pfizer Recent Developments
  31. 8.6 GlaxoSmithKline
  32. 8.6.1 GlaxoSmithKline Company Information
  33. 8.6.2 GlaxoSmithKline Business Overview
  34. 8.6.3 GlaxoSmithKline Antidiabetic Thiazolidinediones Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 GlaxoSmithKline Antidiabetic Thiazolidinediones Product Portfolio
  36. 8.6.5 GlaxoSmithKline Recent Developments
  37. 8.7 AstraZeneca
  38. 8.7.1 AstraZeneca Company Information
  39. 8.7.2 AstraZeneca Business Overview
  40. 8.7.3 AstraZeneca Antidiabetic Thiazolidinediones Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 AstraZeneca Antidiabetic Thiazolidinediones Product Portfolio
  42. 8.7.5 AstraZeneca Recent Developments
  43. 8.8 Novo Nordisk
  44. 8.8.1 Novo Nordisk Company Information
  45. 8.8.2 Novo Nordisk Business Overview
  46. 8.8.3 Novo Nordisk Antidiabetic Thiazolidinediones Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Novo Nordisk Antidiabetic Thiazolidinediones Product Portfolio
  48. 8.8.5 Novo Nordisk Recent Developments
  49. 8.9 Bristol-Myers Squibb
  50. 8.9.1 Bristol-Myers Squibb Company Information
  51. 8.9.2 Bristol-Myers Squibb Business Overview
  52. 8.9.3 Bristol-Myers Squibb Antidiabetic Thiazolidinediones Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Bristol-Myers Squibb Antidiabetic Thiazolidinediones Product Portfolio
  54. 8.9.5 Bristol-Myers Squibb Recent Developments
  55. 8.10 Boehringer Ingelheim
  56. 8.10.1 Boehringer Ingelheim Company Information
  57. 8.10.2 Boehringer Ingelheim Business Overview
  58. 8.10.3 Boehringer Ingelheim Antidiabetic Thiazolidinediones Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Boehringer Ingelheim Antidiabetic Thiazolidinediones Product Portfolio
  60. 8.10.5 Boehringer Ingelheim Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Antidiabetic Thiazolidinediones Value Chain Analysis
  2. 9.1.1 Antidiabetic Thiazolidinediones Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Antidiabetic Thiazolidinediones Sales Mode & Process
  6. 9.2 Antidiabetic Thiazolidinediones Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Antidiabetic Thiazolidinediones Distributors
  9. 9.2.3 Antidiabetic Thiazolidinediones Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst